ABSTRACT Chicken infectious anemia virus is an important pathogen that causes severe anemia and immunosuppression in chickens, leading to serious economic losses worldwide in the poultry industry. However, no commercialized inactivated vaccine, subunit vaccine, or genetically engineered vaccine that is effective for controlling this virus is available. In this study, 3 recombinant plasmids were constructed to produce corresponding viral proteins in an Escherichia coli system. The immune effects of the subunit proteins accompanied by CpG-ODN or Freund's immune adjuvants were evaluated and analyzed in systemic animal experiments. The results showed that VP1 induced the highest antibody titers with the participation of VP2 protein, indicating better protection under combined treatment, and the CpG-ODN adjuvant induced higher antibody titers and smaller dispersion of antibody titers than Freund's adjuvants. This is the first study to demonstrate that VP1 protein formulated with VP2 and CpG-ODN adjuvant can induce highest antibody titers and markedly enhance the immune response, indicating its promise as a vaccine candidate.
INTRODUCTION
Chicken infectious anemia virus (CIAV), belonging to the Gyrovirus genus, Anelloviridae family, causes atrophy of bone marrow hematopoietic tissue and lymphatic tissues (e.g., thymus) in young chickens, leading to anemia and immune suppression, and can be spread both horizontally and vertically (Hoop, 1992; Miller and Schat, 2004) . After its first report in 1979 (Yuasa et al., 1979) , CIAV has been detected worldwide and has caused huge economic losses (Rosenberger and Cloud, 1989; Zhou et al., 1996; Ducatez et al., 2006; Natesan et al., 2006; Craig et al., 2009; Kim et al., 2010; Smuts, 2014; Gholami-Ahangaran, 2015; Ganar et al., 2017; Li et al., 2017) .
As a non-enveloped icosahedral single-stranded DNA virus, the genome of CIAV is approximately 2.3 kb and contains three open reading frames (ORFs) in the negative-sense genome encoding 3 proteins, VP1, VP2, C 2018 Poultry Science Association Inc. Received July 8, 2018. Accepted October 12, 2018. 1 These authors contributed equally to this work 2 Corresponding authors: vetiascaas@126.com (XG); zhaopeng@sdau. edu.cn (PZ) and VP3. VP1 protein (51 kDa) is the sole structural protein assembled into the CIAV capsid (Todd et al., 1990) . Immunogenicity studies have shown that VP1 is the major immunogenic protein that allows elicitation of host-produced virus neutralizing antibodies. VP2 protein (28 kDa) is a scaffolding protein that helps VP1 form the correct conformation and exposes its neutralizing epitopes (Peters et al., 2002; Lacorte et al., 2007) . Both VP1 and VP2 are targets of neutralizing antibodies (Koch et al., 1995) . VP3 protein (13 kDa) is a non-structural protein that induces apoptosis within infected chicken cells and human tumor cell lines (DanenVan Oorschot et al., 1997; Zhang et al., 2003; Noteborn, 2005) .
There are some limitations to currently available vaccines (live attenuated/inactivated) for CIAV. For example, it is difficult for CIAV to reach high titers in embryos/cell cultures. Residual pathogenicity and a risk of reversion to virulence restrict the development and application of live attenuated CIAV vaccine. The 3 CIAV viral proteins have been expressed in several different systems to develop subunit vaccines or diagnostic kits (Lien, et al., 2012; Lai, et al., 2013; Shen, et al., 2015) . However, the efficacy of individual and combined application of the CIAV viral proteins as antigens to VP1-F  5 -GCGGAATTCATGGCAAGACGAGCTC-3  832-857  1350  VP1-R  5 -GGGCTCGAGTCAGGGGGGCGAC-3  2150-2181  VP2-F  5 -GCGGAATTCATGCACGGGAACG -3  359-382  651  VP2-R  5 -GGGCTCGAGTCACACTATACGTACCG-3  983-1009  VP3-F  5 -GCGGAATTCATGAACGCTCTCCA-3  465-488  366  VP3-R  5 -GGGCTCGAGTTACAGTCTTATACACC-3  804-830 a F and R represent upstream and downstream primers, respectively.
compare their antigenicity against chicken remains unclear. In this study, the enhanced effects of adjuvant cytosine-phosphate-guanine oligodeoxynucleotide (CpG-ODN) on immune protection of subunit vaccines containing individual or combined applications of the CIAV viral proteins were compared with those of Freund's adjuvants.
MATERIALS AND METHODS

Ethics Statement
The animal care and use protocol was approved by the Shandong Agricultural University Animal care and use Committee (SDAUA-2016-002) . All of the experimental animals of this study were cared for and maintained throughout of the experiments strictly following the ethics and biosecurity guidelines approved by the Institutional Animal Care and Use Committee of Shandong Agricultural University.
Cells, Virus, Plasmids, Animals, and Adjuvants
The CIAV strain (SD15, GenBank accession number: KX811526) was isolated from a breeding chicken farm in northern China and cultured in MDCC-MSB1 cells (purchased from Cell Lines Service, Eppelheim, Germany). The pET28a simple vector was purchased from Dalian Takara Biotechnology Co., Ltd. (Dalian, China) and used for plasmid-cloning experiments. The BL21 (DE3) cells expression vector (Invitrogen, Carlsbad, CA, USA) was obtained commercially. Specific pathogen-free (SPF) chickens were purchased from SPAFAS Co. (Jinan, China; a joint venture with Charles River Laboratory, Wilmington, MA, USA). The Freund's adjuvant used in this study was purchased from the Sigma (St. Louis, MO, USA).
CpG-ODN Adjuvant
A CpG-enriched pUC18 plasmid containing 20 copies of CpG-ODN 2006 (sequence: 5 -TCGTCGTT TTGTCGTTTTGTCGTTTTGTCGTTTTGTCGTT-3 ) was generated by tandem insertion of four copies of CpG-ODN 2006 into the multiple cloning site of the pUC18 vector (Preliminary experiments showed that there is no effect of the pUC18 on the immune response against CIAV subunit vaccines). The resulting pUC18-CpG was amplified in Escherichia coli, which were then cultured by fermentation, and the recombinant plasmid was purified using the large-scale plasmid-purification method (Zhang et al., 2008) . After alkali lysis of E. coli, the plasmid was selectively precipitated from the supernatant using cetyltrimethylammonium bromide and then purified using potassium acetate and Triton X-114 to remove host protein and endotoxin, respectively. Endotoxin removal was verified using limulus amebocyte lysate tests. The CpG motif and copy number in the plasmid were confirmed by sequencing. Finally, the purified plasmid was dissolved at 10 mg/mL in endotoxin-free PBS and stored at -20
• C until further use.
Construction of the Expression Vectors
Primers for VP1, VP2, and VP3 were designed and synthesized according to the CIAV-SD15 sequence (Table 1) . Three viral protein genes were amplified individually with DNA extracted from CIAV strain SD15-infected MDCC-MSB1 cells as a template. The PCR products were cloned into the pET28a simple vector by restriction enzyme digestion. The recombinant plasmids were confirmed by DNA sequencing and named as pVP1, pVP2, and pVP3.
Expression and Purification of CIAV Viral Proteins in E. Coli System
The recombinant plasmids pVP1, pVP2, and pVP3 were transformed into E. coli BL21 (DE3) cells, which were grown in lysogeny broth (LB) medium (Solarbio, Beijing, China) in the presence of carbenicillin (fifty mg/mL, Solarbio) at 37
• C. Next, recombinant VP1, VP2, and VP3 protein expression was induced by adding 1 millimole Isopropyl β-D-1-thiogalactopyranoside (IPTG, Solarbio) followed by incubation for 4 h. The 3 viral proteins (containing Histag) were purified using a high-affinity Ni-NTA column (GenScript USA Inc., Nanjing, China). The presence of expressed recombinant proteins was evaluated by 12.5% SDS-PAGE then recognized by western blotting using CIAV-infected positive sera. 
Protein Concentration Assay
Protein concentrations were determined using a BCA Protein Assay Kit (Tiangen Biotech Co., Ltd. Beijing, China), which contains bovine serum albumin as a protein standard solution.
Animal Trial and Assessment of Immune Response
One-day-old SPF chickens were randomly divided into 10 groups, with 10 chickens in each group, and separately bred in shielded cages with positive filtered air. The immunogenicity study of the CIAV subunit vaccine (VP1, VP2, and VP1+VP2) with the use of adjuvant (CpG-ODN or Freund's) was conducted in accordance with the experimental design presented in Table 2 . After the first immunization, blood samples were collected every week, and the CIAV-specific antibody levels in serum were tested using a Chicken Anemia Virus Antibody Test Kit (IDEXX, USA).
Statistical Analysis
Statistical analysis was performed using the SPSS statistical software package for Windows version 17.0 (SPSS Inc. Chicago, Illinois, USA). P<0.05 was considered statistically significant.
RESULTS
Three CIAV Viral Proteins were Expressed and Purified
In this study, full-length CIAV-SD15 VP1, VP2, and VP3 genes were amplified to express the VP1, VP2, and VP3 proteins (Fig. 1) . The recombinant plasmids were expressed in E. coli, and the His-tagged proteins were purified by high-affinity chromatography followed by gel filtration chromatography. Protein bands at approximately 51 kDa for VP1, 24 kDa for VP2, and 13 kDa for VP3 were visualized by SDS-PAGE ( Fig. 2A , B, and C). The purified recombinant proteins were also detected in CIAV-infected positive serum (Fig. 2a, b, c) .
CIAV Antibody-Positive Rates in Different Groups
After primary immunization, we measured the CIAV antibody levels in each group by enzyme-linked immunosorbent assay for 5 wk. By counting the positive and negative serum samples, we determined the positive rates of CIAV antibody in each group (Table 3) . The results showed that only group VP1+VP2+C and group VP1+VP2+F were antibody-positive at 1 week after immunization, while the positive rate of the VP1+VP2+C group was 20% higher than that of the VP1+VP2+F group; the difference was significant (P < 0.05). A positive rate of 40% was observed in the positive control group, while all other groups were negative. At 2 wk after primary immunization, all groups showed different proportions for the positive rate, and the positive rates of group VP1+VP2+C and group positive control reached 100%. The positive rates of CpG groups were higher than those of the corresponding Freund's groups, indicating that the CpG-ODN has a more enhanced humoral response than Freund' s adjuvants. At weeks 4 and 5, the antibody-positive rate reached 100% A positive chicks/all chicks. The CIAV-specific antibody levels in serum were tested using a Chicken Anemia Virus Antibody Test Kit (IDEXX, USA). Different lowercase superscript letters indicate that the difference is statistically significant within a column (P<0.05) based on Duncan's multiple-range test.
in all groups except the negative control group. These results indicate that the VP1, VP2, and VP3 proteins expressed in this study are sufficiently effective and stable to induce the corresponding positive antibodies.
Antigenic Characterization of Subunit Proteins with Different Adjuvants
To characterize the antigenic properties of subunit proteins in immune response, the antibody titers of all chickens at different times were determined, as shown in Figure 3 . Antibody titers showed increasing trends in all groups. Under the same immune adjuvant conditions, the antibody titer induced by VP1 was lower than that of VP2 and VP3, and the combination use of VP1+VP2 induced higher antibody titers than VP1, VP2, and VP3. In contrast, the antibody titers induced in groups using CpG-ODN were significantly higher than those in corresponding groups using Freund's immune adjuvants. At week 5, the antibody titer in group VP1+VP2+C (titer: 8124) was approximately 2-fold higher than that in group VP1+F (titer: 4028) and was only approximately 800 titers lower than that in the positive control group (titer: 8947). Serums from all chicks were collected at different intervals of the experiment to determine the concentrations of CIAV antibody, which was represented as antibody titers. The CIAV-specific antibody levels in serum were tested using a Chicken Anemia Virus Antibody Test Kit (IDEXX, USA).
CpG-ODN Shows Better Immune Effect than Freund's Immune Adjuvants
As is shown in Figure 4 , we used adjuvant as the sole variable to plot antibody titers after 4 wk. The Figure 4 The effect of different adjuvants on the antibody levels induced by different subunit protein at 5 wk age. Serums from all chicks were collected at 5 wk age of the experiment to determine the concentrations of CIAV antibody in different groups, which was represented as CIAV antibody titer (Mean value ± error). The CIAV antibody titer of group CpG-ODN was compared with that of the corresponding group Freund's ( * P < 0.05) based on Duncan's multiple-range test.
results indicated that the CpG-ODN adjuvant induced higher antibody titers than the Freund's immune adjuvants and that the antibody titer gap between the two adjuvants was approximately 2000; this difference was significant (P < 0.05). The smaller dispersion of antibody titers in the CpG-ODN adjuvant groups supported the capability of different subunit proteins to be steady and showed minimal fluctuations in the immune reaction.
DISCUSSION
CIAV has caused huge economic losses in the poultry industry worldwide and not only induces chicken aplastic anemia (Rosenberger and Cloud, 1989; Zhou et al., 1996; Ducatez et al., 2006; Natesan et al., 2006; Craig et al., 2009; Kim et al., 2010; Smuts, 2014; GholamiAhangaran, 2015; Ganar et al., 2017; Li et al., 2017) , but also affects the growth and immune response of chickens (Hoop, 1992; Miller and Schat, 2004) . CIAV can interact with Marek's disease virus or infectious bursal disease virus to cause severe clinical symptoms (Haridy et al., 2009 (Haridy et al., , 2012 Vaziry et al., 2013) . Currently, there is no commercialized inactivated vaccine, subunit vaccine, or genetic engineering vaccine that effectively controls CIAV. The only vaccine that has been applied on chicken farms is the Cux-1 CIAV live vaccine (AviProThymovac) produced by Roman Animal Health Co., Ltd. Chickens of a suitable age for drinking water containing Cux-1 CIAV live vaccine can provide maternal antibodies to their progeny. However, considering the subclinical status of adult chickens after using the vaccine and low maternal antibody titers of the progeny, this vaccine has not been formally introduced in China and many other countries. Therefore, it is important to develop a safe and efficient vaccine for controlling CIAV.
Because CIAV cultured in chicken embryos or MDCC cells cannot reach high virus titers, the expression of CIAV protein is an effective method for preparing subunit vaccines to prevent CIAV rather than developing inactivated vaccines. Several different systems have been developed to express the 3 CIAV viral proteins for use in subunit vaccines (Shen, et al., 2015) or to develop diagnostic enzyme-linked immunosorbent assay kits to detect the presence of CIAV antibodies (Lien et al., 2012; Lai et al., 2013) . However, no systematic studies have compared the immunological properties of VP1, VP2, and VP3 proteins. In this study, the three CIAV viral proteins were expressed in E. coli cells, and systematic experiments were conducted for antigenic characterization of subunit proteins in the immune response. The results of this study showed that all 3 expressed proteins induced the production of corresponding antibodies. In accordance with a previous study (Lai et al., 2013) , as the sole structural protein, lower immunoreactivity was observed with the VP1 subunit proteins (Fig. 3) , which showed poor immunogenicity. However, VP1 is the major immunogenic protein, and VP2 is a scaffolding protein that helps VP1 form the correct conformation and exposes its neutralizing epitopes. Thus, VP1 plus VP2 proteins were used to induce serum antibodies in this experiment. The results showed that the antibody titer in the VP1+VP2 group was significantly higher than that in either the VP1 or VP2 group, demonstrating that VP1 induces higher antibody titers with the participation of VP2 protein, leading to better protection.
The development of immune adjuvants has greatly improved the immune response of animals. Freund's adjuvants and CpG-ODN adjuvant are both effective immune adjuvants capable of enhancing cellular and humoral immune responses. This is the first report to compare the efficacy of CpG-ODN and Freund's immune adjuvants on antibody responses induced by CIAV subunit proteins. In this study, the subunit proteins (VP1, VP2, VP3, and VP1+VP2) plus CpG-ODN adjuvant can induce better CIAV specific antibody responses than Freund's adjuvants. Not only did a higher number of birds show immune responses, but also an earlier positive antibody response was observed in these groups (Table 2) . Moreover, compared with the Freund's adjuvants, the CpG-ODN adjuvant induced higher antibody titers and smaller dispersion of antibody titers (Fig. 4) . Consequently, our findings demonstrate that the CpG-ODN adjuvant is a good candidate for CIAV subunit vaccines in the future.
In conclusion, three CIAV viral proteins were expressed successfully and efficacy of CpG-ODN and Freund's immune adjuvants on antibody responses induced by those subunit proteins were estimated by systemic experiments. More importantly, this is the first study to demonstrate that VP1 protein formulated with VP2 and CpG-ODN adjuvant induces higher antibody titers and markedly enhances the immune response, making it a very promising vaccine candidate.
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